Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care

By João L. Carapinha

May 5, 2026

Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health educ...
Navigating the Challenges of Patient-Centered AI Systems in Postpartum Depression Care
Patient-centered AI systems can improve care, but moving them from labs to clinics without causing harm remains a critical challenge. A recent qualitative study explored this question by capturing the perspectives of patients, healthcare professionals, and developers, using a postpartum depressio...
JNJ-4804 IBD Therapy Proves Effective for Refractory Inflammatory Bowel Disease
JNJ-4804 IBD therapy offers new hope for patients with hard-to-treat inflammatory bowel disease. This co-antibody treatment combines two proven mechanisms in a single injection. It targets IL-23 and TNF-α pathways at once. Recent Phase 2b results support its move into larger trials. Johnson &a...